Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zopapogene Imadenovec · Papzimeos, PRGN-2012

Vaccine (Adenoviral vector) · Immune activation, directed at human papillomavirus type 6 and 11 proteins · developed by Precigen

Approved FDA, Aug 2025
PGEN Developer
3 Registered trials

What is Zopapogene Imadenovec?

Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy that expresses a fusion antigen of selected regions of human papillomavirus 6 and 11 proteins. It is designed to generate an immune response against HPV 6 and HPV 11 proteins and is studied in recurrent respiratory papillomatosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Papzimeos, PRGN-2012
Drug type
Vaccine (Adenoviral vector)
Targets
human papillomavirus type 6 and 11 proteins (antigen)
Mechanism
Immune activation, directed at human papillomavirus type 6 and 11 proteins
Therapy area
Infectious disease
Developer
Precigen, Inc. (PGEN)
FDA status
Approved as Papzimeos (August 14, 2025), BLA125832 · FDA label
UNII
C525BYS7TP

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 12, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06538480 Phase 4 Recurrent Respiratory Papillomatosis Recruiting PGEN
NCT07901738 Phase 3 Recurrent Respiratory Papillomatosis (RRP) Not yet recruiting PGEN
NCT04724980 Phase 1/2 Recurrent Respiratory Papillomatosis Active not recruiting PGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Juvenile-onset Recurrent Respiratory PapillomatosisPapillomaviridaePapillomavirus InfectionRecurrent Respiratory PapillomatosisRecurrent Respiratory Papillomatosis (RRP)

More from Precigen

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PGEN page.

Follow PGEN, the company behind Zopapogene Imadenovec

See PGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PGEN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.